10-Q: Lifeward Ltd. Reports Q2 2026 Results, Faces Going Concern Doubt

Lifeward Ltd. reported a 16% revenue increase for Q2 2026 but faces substantial doubt regarding its ability to continue as a going concern due to ongoing net losses and negative cash flow.

Summary

• Lifeward Ltd. reported Q2 2026 revenues of $6.6 million, a 16% increase year-over-year, but incurred a net loss of $11.5 million for the quarter and $22.3 million for the six months ended June 30, 2026.
• The company's accumulated deficit reached $307.1 million as of June 30, 2026, and it has substantial doubt about its ability to continue as a going concern.
• Operating expenses increased significantly, particularly in research and development, driven by acquisitions and clinical trial costs.
• Financial expenses rose substantially due to fair value changes in warrant and derivative liabilities and interest expense on convertible notes.
• The company raised capital through various financing activities, including a strategic transaction involving Oramed Pharmaceuticals Inc. and subsequent note issuances.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, substantial doubt about the company's ability to continue as a going concern, and significant increases in financial expenses, despite some revenue growth.

Positives

• Revenue increased by 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of 2025.
• The company strengthened its balance sheet with a proforma cash balance of approximately $11 million after a strategic financing closed on July 6, 2026.
• The acquisition of Oratech in March 2026 expanded the company's strategic initiatives into biomedical technologies.
• The acquisition of Skelable assets in May 2026 is expected to support the development of a powered upper-body robotic exoskeleton.

Negatives

• The company incurred a net loss of $11.5 million for the three months ended June 30, 2026, and $22.3 million for the six months ended June 30, 2026.
• As of June 30, 2026, the company had an accumulated deficit of $307.1 million.
• The company's cash and cash equivalents were $9.4 million as of June 30, 2026, with negative operating cash flow of $9.7 million for the six months ended June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the date of issuance of the financial statements.
• Gross profit margin decreased to 40.9% in Q2 2026 from 43.9% in Q2 2025 due to adverse foreign exchange, revenue sharing expenses, and higher tariffs.
• Research and development expenses increased significantly, including a one-time $4.9 million charge for acquired in-process R&D related to the Oratech acquisition.

Risks

• The company's ability to continue as a going concern is dependent on obtaining necessary financing.
• The company may need to implement measures to manage cash expenditures and preserve liquidity if additional capital cannot be obtained.
• Reliance on a single contract manufacturer for AlterG products makes the company vulnerable to capacity constraints and reduces control over component availability and delivery schedules.
• The company's ordinary shares may be delisted from the Nasdaq Capital Market if it cannot maintain compliance with continued listing requirements.
• The company is subject to risks associated with cybersecurity attacks or incidents.
• The impact of substantial sales of shares by certain shareholders on the market price of ordinary shares.
• Market and other conditions, including inflationary pressures, interest rate and currency rate fluctuations, and geopolitical instability, may disrupt business operations.

Future Outlook

The company expects future growth to be primarily driven by sales of its ReWalk Personal device through expanded coverage and reimbursement, and by increased shipments of its AlterG Anti-Gravity systems. Research and development efforts will focus on product improvements, cost reduction, and integration of acquired technologies. The company anticipates continued operating losses and negative cash flows, requiring additional funding.

Management Comments

• Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of 2025, marking the strongest quarterly revenue performance since the fourth quarter of 2024.
• Strengthened the Company's balance sheet to a proforma cash balance of approximately $11 million.
• Continued successful execution of Lifeward's capital-efficient distribution strategy, expanding patient access through established rehabilitation and durable medical equipment distribution partners.
• Further strengthened Lifeward's restorative healthcare platform, with ongoing investigational device development, combining market-leading rehabilitation technologies with an established reimbursement infrastructure.
• Advanced the ORMD-0801 oral insulin clinical program, with preparations ongoing for the planned Phase 2 U.S. clinical trial.

Industry Context

StockSavvy.ai notes that Lifeward operates in the competitive medical device sector, focusing on rehabilitation and recovery solutions. The company's strategy involves both internal development and strategic acquisitions, aiming to expand its product portfolio and market reach. The increasing focus on biomedical pipeline and oral insulin delivery indicates a diversification strategy beyond traditional exoskeleton and anti-gravity systems.

Comparison to Industry Standards

• The company's revenue growth of 16% in Q2 2026 is a positive sign, but the overall financial performance, including significant net losses and a going concern warning, is a concern when compared to more established medical device companies.
• The substantial increase in R&D expenses, particularly due to acquisitions and clinical trials, is common in the medical device industry for companies developing new technologies, but the scale of the one-time IPR&D charge ($4.9 million) is notable.
• The company's efforts to secure reimbursement from payors like Medicare and German SHIs are critical for adoption, a process that can be lengthy and complex, similar to other innovative medical device companies seeking market access.
• The company's reliance on financing through equity and debt is typical for early-stage or growth-phase medical device companies, but the current situation highlights the high-risk nature of this sector.

Legal Proceedings

• The company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising in the ordinary course of business.
• The company does not believe the outcome of any pending or threatened litigation and other legal matters will have a material adverse effect on its consolidated results of operation, liquidity or financial condition.

Related Party Transactions

• Revenue sharing expense attributable to Oramed Pharmaceuticals Inc. was $97 thousand for the three and six months ended June 30, 2026.
• Net financing expense, including interest expense and changes in fair value of warrant and derivative liabilities related to Oramed Pharmaceuticals Inc., was $7,074 thousand for the three months and $7,470 thousand for the six months ended June 30, 2026.
• Cash acquired in connection with the acquisition of Oratech from Oramed Pharmaceuticals Inc. was $6,500 thousand.
• Proceeds from issuance of Additional Notes to Oramed Pharmaceuticals Inc. were $1,025 thousand for the six months ended June 30, 2026.
• Proceeds from issuance of New Notes, derivative liabilities, and warrant liabilities to Oramed Pharmaceuticals Inc. were $4,397 thousand for the six months ended June 30, 2026.
• Amounts due to Oramed Pharmaceuticals Inc. as of December 31, 2025, were related to a related party arrangement.
• Balances attributable to Oramed Pharmaceuticals Inc. were $3,982 thousand as of June 30, 2026, related to convertible promissory notes, net.
• The acquisition of Oratech involved issuing Ordinary Shares and Pre-Funded Warrants to Oramed, as well as freestanding warrants and revenue sharing payments.
• Certain members of the Company's Board of Directors are affiliated with Oramed.

Stakeholder Impact

• Shareholders: Continued net losses and the going concern warning pose significant risks to shareholder value. Capital raises dilute existing shareholders.
• Creditors: The company's ability to service its debt obligations is a concern given its financial condition, though recent financing may alleviate some pressure.
• Employees: The company's financial instability and potential need for cost-cutting measures could impact employee morale and job security.
• Suppliers: Potential working capital constraints could affect the company's ability to meet its payment obligations to suppliers.
• Customers: Continued product development and potential market expansion are positive for customers seeking rehabilitation solutions.

Next Steps

• Continue to focus on revenue growth through sales of ReWalk Personal device and expansion of coverage and reimbursement.
• Expand shipments of AlterG Anti-Gravity systems through increased penetration of rehabilitation clinics and international distributor networks.
• Focus R&D efforts on product improvements, cost reduction for ReWalk and AlterG, and integration of acquired technologies (Skelable).
• Advance the ORMD-0801 oral insulin clinical program, with preparations for a planned Phase 2 U.S. clinical trial.
• Seek additional sources of financing if more funds are required than anticipated.
• Continue to address the company's cost structure.

Key Dates

Recommendation

The company continues to report substantial net losses, has an accumulated deficit of over $300 million, and faces substantial doubt about its ability to continue as a going concern. While revenue has shown some growth, the increasing financial expenses and the need for continuous capital raises to fund operations present significant risks. The current financial trajectory suggests a high level of risk for investors.

Keywords

medical device, rehabilitation, exoskeleton, spinal cord injury, Oratech acquisition, Oramed Pharmaceuticals, oral insulin, Skelable acquisition